196 related articles for article (PubMed ID: 20485677)
1. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.
Chiriva-Internati M; Yu Y; Mirandola L; Jenkins MR; Chapman C; Cannon M; Cobos E; Kast WM
PLoS One; 2010 May; 5(5):e10471. PubMed ID: 20485677
[TBL] [Abstract][Full Text] [Related]
2. Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.
Mattila JP; Mirandola L; Chiriva-Internati M
J Biomed Mater Res B Appl Biomater; 2019 Jan; 107(1):29-36. PubMed ID: 29504239
[TBL] [Abstract][Full Text] [Related]
3. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
[TBL] [Abstract][Full Text] [Related]
4. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
Choi YS; Hoory T; Monie A; Wu A; Connolly D; Hung CF
Vaccine; 2008 Oct; 26(46):5855-63. PubMed ID: 18771701
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
6. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
7. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258
[TBL] [Abstract][Full Text] [Related]
8. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.
Chang MC; Chen YL; Chiang YC; Chen TC; Tang YC; Chen CA; Sun WZ; Cheng WF
Gene Ther; 2016 Jan; 23(1):38-49. PubMed ID: 26262583
[TBL] [Abstract][Full Text] [Related]
10. Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
Chiriva-Internati M; Wang Z; Salati E; Timmins P; Lim SH
Cancer; 2002 May; 94(9):2447-53. PubMed ID: 12015770
[TBL] [Abstract][Full Text] [Related]
11. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
12. Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.
Varypataki EM; Hasler F; Waeckerle-Men Y; Vogel-Kindgen S; Høgset A; Kündig TM; Gander B; Halin C; Johansen P
Front Immunol; 2019; 10():1548. PubMed ID: 31333674
[TBL] [Abstract][Full Text] [Related]
13. Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells.
Liu Y; Tian X; Jiang S; Ren X; Liu F; Yang J; Chen Y; Jiang Y
Cell Immunol; 2015; 298(1-2):18-24. PubMed ID: 26300426
[TBL] [Abstract][Full Text] [Related]
14. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams SF; Grimm AJ; Chiang CL; Mookerjee A; Flies D; Jean S; McCann GA; Michaux J; Pak H; Huber F; Neal C; Dangaj D; Bassani-Sternberg M; Rusakiewicz S; Facciabene A; Coukos G; Gimotty PA; Kandalaft LE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817208
[TBL] [Abstract][Full Text] [Related]
15. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
17. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
[TBL] [Abstract][Full Text] [Related]
18. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
19. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
